Piper Jaffray Reiterates “Overweight” Rating on Genzyme Corp (NASDAQ: GENZ) - American Banking News |
|
|
American Banking NewsThe Company's product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune ...
|